Intravitreal Bevacizumab Alone or Combined with Macular Laser Photocoagulation for Recurrent or Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion

Hirashima, Takafumi; Chihara, Tomoyuki; Bun, Toshitaka; Utsumi, Takao; Hirose, Miou; Oh, Hideyasu

doi:10.1155/2014/173084

Cited by 5 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Branch retinal vein occlusion (BRVO) is one of the major retinal vascular disorders causing vision loss [1,2], wherein macular edema (ME) is the main culprit for vision impairment. Until recently, the standard of care for ME was grid laser photocoagulation based on the branch vein occlusion (BVO) study [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of leaking capillaries and microaneurysms in the perifoveal capillary network on resolution of macular edema by anti-vascular endothelial growth factor treatment

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Several small clinical trials reported that a combined intravitreal anti-VEGF injection and subsequent macular grid laser photocoagulation could reduce the required number of intravitreal anti-VEGF agent injections [8][9][10][11], but this was refuted by other studies [2,12,13].…”

Section: Introductionmentioning

confidence: 99%

Effect of leaking capillaries and microaneurysms in the perifoveal capillary network on resolution of macular edema by anti-vascular endothelial growth factor treatment

et al. 2016

View full text Add to dashboard Cite

show abstract

“…1 A, B and C). The results of long-term follow-up of these patients showed that 4 patients had a recurrence with CRT ≥ 250 μm, 7 patients did not have a recurrence of macular edema and 3 patients were lost to follow-up after the first review [ 14 ]. These four patients with recurrent macular edema were defined as the recurrence group (Supplementary Fig.…”

Section: Methodsmentioning

confidence: 99%

Recurrence of macular edema in patients with branch retinal vein occlusion: a proteomic study

Liu,

Wang,

Sheng

et al. 2024

BMC Ophthalmol

View full text Add to dashboard Cite

Background Branch retinal vein occlusion (BRVO) is a common retinal vascular disease leading to severe vision loss and blindness. This study aimed to investigate and reveal the pathophysiological mechanisms underlying macular edema (ME) recurrence in patients with BRVO through a proteomic approach. Methods We detected proteins in the aqueous humor of 14 untreated, four refractory, and four post-operative patients with BRVO-ME and 12 age-matched cataract controls using four-dimensional label-free proteomic and bioinformatics analyses. Results In total, 84 proteins exhibited significant differential expression between the BRVO and control samples (fold change [FC] ≥ 1.2 and adjusted p-value < 0.05). Compared to the control group, 43 and 41 proteins were upregulated and downregulated, respectively, in the BRVO group. These proteins were involved in cell adhesion, visual perception, retina homeostasis, and platelet activation. Several significantly enriched signaling pathways included complement and coagulation cascades and platelet activation. In the protein–protein interaction networks generated using the search tool for retrieval of interacting genes (STRING), the fibrinogen alpha chain and fibrinogen beta chain constituted a tightly connected cluster. Many common protein expression trends, such as the fibrinogen alpha chain and fibrinogen beta chain, were observed in both the recurrent and refractory groups. Differentially expressed proteins in the two groups were involved in complement activation, acute-phase response, platelet activation, and platelet aggregation. Important signaling pathways include the complement and coagulation cascades, and platelet activation. Protein–protein interaction analysis suggested that the fibrinogen alpha chain and fibrinogen beta chain constituted a tightly connected cluster. The expression of some differentially expressed proteins shared by the BRVO and the recurrent and refractory groups was reversed in the post-operative group. Conclusions Our study is the first to analyze the proteomics of recurrent, refractory, and post-operative groups treated for BRVO-ME, and may potentially provide novel therapeutic interventions for the recurrence of ME.

show abstract

“…A study showed that combination therapy with IVB and macular laser photocoagulation had fewer effects on BCVA than IVB monotherapy. 50 Another study showed that cataracts and secondary glaucoma were more effective in IVT + GLP compared to the combined effect of IVB + GLP. Still, both treatments were effective in the treatment of macular edema due to branch retinal vascular occlusion.…”

Section: Combination Therapiesmentioning

confidence: 99%

Therapeutic Effects of Combination Therapy and Photobiomodulation Therapy on Retinal Regeneration

et al. 2022

View full text Add to dashboard Cite

Introduction: Many systemic and ocular diseases cause macular edema (ME). Macular edema is seen in two primary forms; the first is diffuse thickening of the macula, and the other is a macula with a distinct petaloid (cloverleaf) appearance called cystoid macular edema. Macular edema has a known role in the reduction of visual equity, and many options have been proposed for the reversal of this condition. Methods: Articles on the effects of macular laser grid photocoagulation on diabetic macular edema (DME) or cystoid macular edema published between 2000 and 2022 were collected from PubMed, Google Scholar, and Web of Science. The following keywords were used for the search: "macular laser photocoagulation", "macular edema", "cystoid macular edema", "intravitreal pharmacotherapies", and "antivascular endothelial growth factor". Two hundred nineteen articles were found in google scholar and 165 articles in PubMed, and a total of 58 articles were included in the study after applying the exclusion criteria. Results: We investigated the effects of various lasers photocoagulation such as Focal and/or grid macular laser, subthreshold micropulse laser (SMPL), as well as intravitreal pharmacotherapies with triamcinolone acetonide, and fluocinolone, and extended released intraocular implants such as Ozurdex, Retisert, Iluvien, and anti-vascular endothelial growth factors such as bevacizumab (Avastin), Eyela, and Lucentis. Corticosteroids were more effective than lasers, although some researchers have found that lasers and combined lasers and corticosteroids are more effective. In addition, some studies have shown that the frequency and concentrations of intravitreal pharmacotherapies are effective in increasing visual outcomes.Conclusion: The results of the studies showed that the combined intravitreal corticosteroids are much more effective in improving visual acuity (VA) than a single corticosteroid, and the low concentration of the drug is safer. Still, corticosteroids have side effects such as increased intraocular pressure and glaucoma. Therefore, combining the medication with a laser is much more reasonable than each alone. Also, the subthreshold photocoagulation laser (670 nm) is better at reducing the central macular thickness (CMT) and improving VA than the micro pulse yellow laser and pan-retinal photocoagulation (PRP).

show abstract

Intravitreal Bevacizumab Alone or Combined with Macular Laser Photocoagulation for Recurrent or Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion

Cited by 5 publications

References 25 publications

Effect of leaking capillaries and microaneurysms in the perifoveal capillary network on resolution of macular edema by anti-vascular endothelial growth factor treatment

Effect of leaking capillaries and microaneurysms in the perifoveal capillary network on resolution of macular edema by anti-vascular endothelial growth factor treatment

Recurrence of macular edema in patients with branch retinal vein occlusion: a proteomic study

Therapeutic Effects of Combination Therapy and Photobiomodulation Therapy on Retinal Regeneration

Contact Info

Product

Resources

About